The older generation of GH secretagogues — more raw potency, more side effects. Here's exactly how they compare to each other and why Ipamorelin became the gold standard.
Last updated: March 2026
All three peptides — Hexarelin, GHRP-2, and GHRP-6 — belong to the same pharmacological class: synthetic ghrelin receptor agonists (GHS-R1a agonists). They mimic ghrelin, your body's primary hunger and GH-release hormone, to drive large pulses of growth hormone from the pituitary.
All three peptides bind and activate the growth hormone secretagogue receptor 1a (GHS-R1a) — the same receptor targeted by the endogenous hunger hormone ghrelin. This triggers a rapid GH pulse from pituitary somatotrophs.
Unlike exogenous HGH (continuous elevation), GHRPs produce sharp, physiological-style GH pulses that last 60–120 minutes. These pulses mimic natural GH secretion patterns, preserving pituitary sensitivity over time — though desensitization still occurs with all three.
Because they mimic ghrelin — the primary hunger hormone — all three stimulate appetite to varying degrees. GHRP-6 is notorious for causing intense hunger within 30–60 min of injection. Hexarelin and GHRP-2 cause less hunger but still significantly more than Ipamorelin.
A key limitation of these older GHRPs: they also activate the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol and prolactin. This is a non-selective effect that Ipamorelin was specifically engineered to avoid. Higher cortisol during GH optimization is counterproductive for body composition.
All three GHRPs work best when paired with a GHRH analog (CJC-1295, Sermorelin). The GHRH analog amplifies the GH pulse signal via a separate receptor; the GHRP triggers release. Together, they produce a GH pulse 5–10× greater than either alone — the basis of the classic stack.
Continuous use of GHS-R1a agonists leads to receptor downregulation. Hexarelin desensitizes fastest (2–4 weeks), making cycle management essential. GHRP-2 and GHRP-6 desensitize more slowly but still require cycling. Ipamorelin shows the slowest desensitization profile.
Mechanism: Hexarelin is a 6-amino acid synthetic peptide that acts as a potent, non-selective GHS-R1a agonist. It also has a unique secondary mechanism — direct cardioprotection via CD36 receptor binding, completely independent of the GH axis.
GH Potency: In head-to-head human studies, Hexarelin consistently produces the largest GH pulses of any synthetic GHRP. GH increases of 10–15× baseline have been documented at standard doses, significantly exceeding GHRP-2, GHRP-6, and Ipamorelin.
Cardioprotection: Hexarelin's CD36 receptor activity is genuinely unique. Animal models of myocardial infarction show Hexarelin directly reduces cardiac apoptosis, improves post-ischemia function, and increases left ventricular contractility. This is a GH-independent mechanism no other GHRP shares.
Side Effects: The trade-off for raw potency is poor selectivity. Hexarelin produces significant cortisol and prolactin elevation — more than GHRP-2, far more than Ipamorelin. Water retention, fatigue, and hunger are common at higher doses.
Desensitization: The fastest of any GHRP. GH response begins declining after as little as 2 weeks of daily use. Most protocols limit cycles to 2–4 weeks with equal time off. This severely limits its utility for ongoing GH optimization vs. Ipamorelin's more sustainable profile.
Key Research: Ghigo et al., 1994 (J Clin Endocrinol Metab) documented supraphysiological GH pulses in healthy adults. Torsello et al. established CD36 cardioprotection. Phase 1/2 human safety data exists.
Mechanism: GHRP-2 is a synthetic hexapeptide GHS-R1a agonist with moderately selective action. It produces strong GH pulses — significantly more than Ipamorelin, less than Hexarelin — while causing moderate cortisol and prolactin elevation.
Clinical History: GHRP-2 (Pralmorelin) achieved regulatory approval in Japan for GH deficiency diagnostic testing. This is the only GHRP outside Hexarelin with formal regulatory recognition. The diagnostic test involves a single 100mcg injection to measure GH response.
Selectivity: GHRP-2 sits between Hexarelin (least selective) and Ipamorelin (most selective). It causes more cortisol and prolactin elevation than Ipamorelin but significantly less than Hexarelin. Appetite stimulation is moderate — more than Ipamorelin, far less than GHRP-6.
Use Cases: GHRP-2 found a niche among researchers wanting more GH potency than Ipamorelin provides, without GHRP-6's extreme hunger effects. It's often compared to a "middle ground" GHRP — stronger than Ipamorelin, cleaner than GHRP-6.
Desensitization: Slower than Hexarelin, faster than Ipamorelin. Continuous use over 4–8 weeks typically shows declining GH response. Cycling protocols (4–6 weeks on, 2–4 weeks off) are standard.
Key Research: Chapman et al. 1997 (J Clin Endocrinol Metab) showed robust GH responses in healthy men. Multiple European and Japanese studies confirm 7–8× baseline GH increases at 1 mcg/kg.
Historical Significance: GHRP-6 was the first synthetic GHRP discovered, emerging from Merck research in the 1970s–80s that eventually led to the discovery of the ghrelin receptor pathway itself. It's the grandfather of this entire class of peptides.
Appetite Effect: GHRP-6 produces the strongest appetite stimulation of any GHRP — often described as extreme, overwhelming hunger within 30–60 minutes of injection. This is a direct consequence of its potent ghrelin receptor activation. For some users in bulking or wasting conditions, this is the desired effect.
GH Pulse: Solid GH release — approximately 6× baseline at standard doses. Less than GHRP-2 and Hexarelin, but meaningful. The GH pulse is overshadowed by the hunger side effect for many users.
Therapeutic Niche: GHRP-6's extreme appetite stimulation was studied for cachexia (wasting conditions), anorexia, and eating disorders where caloric intake is the limiting factor. A few centers used it for post-surgical recovery and chemotherapy-related wasting.
Cortisol/Prolactin: Similar profile to GHRP-2 — moderate elevation, more than Ipamorelin, less than Hexarelin. Not ideal for body composition optimization where cortisol management matters.
Key Research: Bowers et al. established foundational GHRP-6 pharmacology. Ghigo et al. (1994) compared GH responses across GHRPs in healthy adults. Penalva et al. studied appetite and metabolic effects.
Side-by-side breakdown across every key metric. Ipamorelin is included as the modern gold standard for comparison.
| Metric | 🔥 Hexarelin | 💉 GHRP-2 | 🍔 GHRP-6 | ⭐ Ipamorelin (reference) |
|---|---|---|---|---|
| GH Pulse Strength | Highest ~10-15× baseline |
High ~7-8× baseline |
Moderate-High ~6× baseline |
Moderate ~4-5× baseline |
| GH Selectivity | Low | Moderate | Moderate | Highest ✓ |
| Cortisol Elevation | High ↑↑ | Moderate ↑ | Moderate ↑ | Minimal ✓ |
| Prolactin Elevation | High ↑↑ | Moderate ↑ | Moderate ↑ | Minimal ✓ |
| Appetite Stimulation | Moderate-High | Moderate | Extreme ↑↑↑ | Minimal ✓ |
| Desensitization Rate | Fast 2-4 weeks |
Moderate 4-8 weeks |
Moderate 4-8 weeks |
Slowest ✓ 8-12+ weeks |
| Route | SubQ injection | SubQ injection | SubQ injection | SubQ injection |
| Typical Dose | 100-200mcg 1-2x/day |
100-300mcg 2-3x/day |
100-300mcg 2-3x/day |
200-300mcg 1-3x/day |
| Cycle Length | 2-4 weeks on 4+ weeks off |
4-8 weeks on 2-4 weeks off |
4-8 weeks on 2-4 weeks off |
8-12+ weeks continuous use possible |
| Unique Advantage | CD36 cardioprotection | Japan diagnostic approval | Appetite/cachexia therapy | Best side-effect profile |
| Regulatory Status | Research only | Research (Japan diagnostic use) | Research only | Research only |
| Human Clinical Data | Phase 1/2 ✓ | Multiple trials ✓ | Multiple trials ✓ | Phase 1/2 ✓ |
Ipamorelin was developed by Novo Nordisk in the late 1990s with a specific engineering goal: match the GH-releasing potency of existing GHRPs while eliminating the off-target HPA axis effects. Raun et al. (1998) published the pivotal study demonstrating that Ipamorelin selectively stimulates GH release with no significant change in ACTH, cortisol, or prolactin at therapeutic doses — the first GHRP to achieve this profile.
Cortisol is catabolic — it breaks down muscle and promotes fat storage. Using a GH secretagogue that also elevates cortisol partially undermines the muscle-sparing, fat-mobilizing goals of GH optimization. Ipamorelin's cortisol-neutral profile makes every GH pulse "cleaner" for body composition outcomes.
Ipamorelin shows the slowest receptor downregulation of any synthetic GHRP. Users can run 8–12+ week cycles without dramatic GH response loss, compared to Hexarelin's 2–4 week ceiling. This makes long-term GH axis optimization practical and sustainable.
Ipamorelin's selective receptor engagement produces minimal appetite stimulation — a critical advantage for body recomposition. GHRP-6's extreme hunger can drive hundreds of surplus calories per injection. Ipamorelin lets you control caloric intake without fighting post-injection cravings.
The only meaningful sacrifice with Ipamorelin is raw GH pulse height. Hexarelin produces 2–3× more GH per injection. Whether this translates to proportionally better outcomes in body composition, recovery, or anti-aging is unclear — IGF-1, not peak GH, is the primary downstream mediator. Ipamorelin's IGF-1 elevation is clinically meaningful.
Ipamorelin is the default choice for most use cases. Here's when the older generation still has a role:
The most common real-world scenario: Advanced users sometimes run a 2-4 week Hexarelin "blast" between longer Ipamorelin cycles to prevent receptor adaptation and briefly maximize GH output — then return to Ipamorelin as their base. This approach leverages Hexarelin's potency while minimizing its desensitization liability.
Standard research dosing ranges from published literature and clinical investigation. Always start at the low end.
Essential equipment for SubQ peptide protocols. Always use proper sterile technique.
Affiliate links help support MeetPeptide at no extra cost to you.
This content is for educational and informational purposes only. Hexarelin, GHRP-2, and GHRP-6 are research peptides and are not approved by the FDA for human therapeutic use. This article does not constitute medical advice, diagnosis, or treatment recommendations. Do not use these substances without consulting a qualified healthcare provider. Individual responses to peptides vary, and these compounds carry real risks including cortisol elevation, prolactin elevation, rapid desensitization, and unknown long-term effects. Always obtain bloodwork before and during any peptide protocol. The information presented here is based on published research and is provided solely for educational awareness of the scientific literature.